Osimertinib: a new drug for non-small cell lung cancer
HE Heng;HUANG Lu;XU Yong;Humanwell Healthcare Co.;Ltd.;Hubei Bio-pharmaceutical Industrial Technological Institute Inc.;

..............page:1801-1806

Applying multi-factor assessment method in material classification in pharmaceutical manufacturing
JIANG Jin-di;YE Chao;YU Yu-qing;ZHENG Qiang;Peking University;Zhejiang Medicine Co.;Ltd.Xinchang Pharmaceutical Factory;GSK Co.;Ltd.;Center for Pharmaceutical Information and Engineering Research;Peking University;College of Engineering;Peking University;

..............page:1807-1813

A prospect theory-based method for selecting new drug R&D project
HUANG Zhe;LI Hui;Faculty of Business Administration;Shenyang Pharmaceutical University;

..............page:1814-1819

Parameter analysis and application of Binomial Tree Model in the value evaluation of new drug projects
CHAI Qian-wen;ZHAO Rui;LI Yun-fei;YANG Yue;School of Business Administration;Shenyang Pharmaceutical University;Tasly Holding Group;National Main Laboratory of Innovative Chinese Medicine Key Technology;

..............page:1820-1825

Study on FDA procedures of drug labeling revision
LI Xiao-yu;TIAN De-long;JU Meng-qi;YANG Yue;School of Business Administration;Shenyang Pharmaceutical University;

..............page:1826-1832

Revision process and interpretation of Clinical Trial Guideline( 2012 edition)for New Traditional Chinese Medicine Drugs in Cancer Treatment
LI Jie;LIN Hong-sheng;Oncology Department of Guang’an Men Hospital;China Academy of Chinese Medicine Sciences;

..............page:1833-1837

Proposals for refinement and standardization of muscle irritation test methods
WU Yan-lin;WANG Ping-ping;ZHANG Yuan;WU Gui-yan;GAO Hua;National Institutes for Food and Drug Control;Department of Clinic;Air Force Logistics;

..............page:1838-1844

Repeated dose toxicity of engineered chimeric murine / human anti-CD20 monoclonal antibody IBI301
LIU Li;LIN Zhi;QI Wei-hong;WEN Nie;XIE Yin;MIAO Yu-fa;JIANG Hua;YANG Yan-wei;LI Jia;LIU Yun-long;CHENG Yuan-guo;WANG Ju-feng;LI Bo;National Center for Safety Evaluation of Drugs;National Institute for Food and Drug Control;Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs;Innovent Biologics;Inc.;Institute of Microbiology and Epidemiology;Academy of Military Medical Sciences;

..............page:1845-1854

Quality study of phosphatidyl choline Cu / Zn superoxide dismutase
FU Zhi-hao;HAN Chun-mei;LI Yong-hong;WANG Lan;TAO Lei;LI Xiang;BI Hua;RAO Chun-ming;WANG Jun-zhi;Division of Recombinant Products;National Institutes for Food and Drug Control;Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products;

..............page:1855-1860

Detection of affinity between therapeutic monoclonal antibodies and neonatal Fc receptor using biolayer interferometry
ZHANG Feng;WU Gang;YU Chuan-fei;WANG Wen-bo;GAO Kai;WANG Lan;National Institutes for Food and Drug Control;Division of Monoclonal Antibody Products;Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Product;

..............page:1861-1867

Progress in research of the cell models of drug-resistant hepatitis C virus
WEI Jia-jia;TANG Bo;XU Bing-fa;QIN Kan;Department of Pharmacy;The Third Hospital Affiliated to Anhui Medical University;Pharmacy Collage of Anhui Medical University;

..............page:1868-1871

Research progress of the preparation technology and pharmacological effect of cycloastragenol
ZHANG Shi-di;LU Jun-kun;YAN Ji-zhong;ZHANG Hui;Zhejiang University of Technology;

..............page:1872-1875

Empirical research of the rights and responsibilities of clinical research associate in clinical trials
YANG Fan;TAO Tian-tian;WANG Meng-yuan;YAO Wen-bing;SHAO Rong;National Drug Policy and Medical Industry Economy Research Center of China Pharmaceutical University;

..............page:1876-1880

System of clinical trial liability insurance compensation for subjects in China
YANG Fan;WANG Meng-yuan;TAO Tian-tian;YAO Wen-bing;SHAO Rong;National Drug Policy and Medical Industry Economy Research Center of China Pharmaceutical University;

..............page:1881-1885

Uncertainty evaluation for the determination of reserpine concentration in human plasma by LC-MS / MS
ZHANG Shuo;QI Wen-yuan;LI Bo;SHI Ai-xin;HU Xin;CHENG Gang;Shenyang Pharmaceutical University;Department of Pharmcy;Beijing Hospital;Ministry of Public Health;Key laboratory of Drug Clinical Risk and Individual Applications Assessment in Beijing;

..............page:1886-1892

Efficacy and safety of paliperidone and aripiprazole in the treatment of autism
LI Yi-chen;MA Jun;XU Han-ming;YANG Guang-yuan;ZHANG Jun-cheng;Wuhan Mental Health Center;Tongji Medical College;Huazhong University of Science and Technology;

..............page:1893-1897

Synthesis and antitumor activity of novel diarylmethenecycloalkane derivatives
LIU Zong-ying;GAO Yan;JIN Jie;LI Zhuo-rong;Center for Drug Evaluation;CFDA;Institute of Medicinal Biotechnology;Chinese Academy of Medical Sciences and Peking Union Medical College;

..............page:1898-1902

Comparison of three methods for establishing rat models of atherosclerosis
LAI Ling;LIU Hua-gang;CHEN Ming;LIU Guan-ping;Guangxi Medical University;Guangxi Wuzhou Pharmaceutical Group Co.;Ltd.;

..............page:1903-1908

Curcumol induces apoptosis of U87 cells via the PI3K/AKT/mTOR pathway
ZHANG Chun;LI Qing-yi;DONG Hai-ying;NIU Jian-guo;NIU Ying-cai;WANG Feng;Ningxia Key Laboratory of Cerebrocranial Diseases;Qiqihaer Medical University;Department of Neurosurgery;the General Hospital of Ningxia Medical University;

..............page:1909-1912

Interstitial lung disease induced by gefitinib:one case report and a review of the literature
LIU Dai-wei;CUI Hui-juan;PENG Yan-mei;SONG Ya-zhong;DUAN Hua;QIU Yu-qin;Beijing University of Traditional Chinese Medicine;Department of Oncology;China-Japan Friendship Hospital;

..............page:1913-1916

Warfarin resistance: case report of 2 patients and the literature analysis
ZHU Ming-mei;XU Hang;XU Jing;Nanjing Children’s Hospital Affiliated to Nanjing Medical University;Department of Pharmacy;Drum Tower Hospital Affiliated to Nanjing University Medical School;

..............page:1917-1920